CUFinder

Warren Mason

Warren Mason

University of Toronto

H-index: 68

North America-Canada

Contact Warren Mason

About Warren Mason

Warren Mason, With an exceptional h-index of 68 and a recent h-index of 47 (since 2020), a distinguished researcher at University of Toronto, specializes in the field of Neurology, Neuro-Oncology, Glioblastoma, Brain Cancer, Clinical Research.

His recent articles reflect a diverse array of research interests and contributions to the field:

A Randomized, Double-blind, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Mutant IDH1/2 Diffuse Glioma (INDIGO): Analysis of Health-related Quality of Life …

Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial

Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma

Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults

Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma

Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma

QOL-26. A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2DIFFUSE GLIOMA (INDIGO …

Focal Adhesion Kinase as a Therapeutic Target for Meningiomas With Somatic Neurofibromatosis Type 2 Mutations

Warren Mason Information

University

Position

Princess Margaret Cancer Centre

Citations(all)

62490

Citations(since 2020)

25204

Cited By

47710

hIndex(all)

68

hIndex(since 2020)

47

i10Index(all)

176

i10Index(since 2020)

131

Email

University Profile Page

Google Scholar

Warren Mason Skills & Research Interests

Neurology

Neuro-Oncology

Glioblastoma

Brain Cancer

Clinical Research

Top articles of Warren Mason

A Randomized, Double-blind, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Mutant IDH1/2 Diffuse Glioma (INDIGO): Analysis of Health-related Quality of Life …

2024/4/14

Mehdi Touat
Mehdi Touat

H-Index: 19

Warren Mason
Warren Mason

H-Index: 46

Matthias Holdhoff
Matthias Holdhoff

H-Index: 24

Yoshiki Arakawa
Yoshiki Arakawa

H-Index: 23

Wolfgang Wick
Wolfgang Wick

H-Index: 92

James Perry
James Perry

H-Index: 30

Dan Zhao
Dan Zhao

H-Index: 14

Islam Hassan
Islam Hassan

H-Index: 11

Timothy Cloughesy
Timothy Cloughesy

H-Index: 78

Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial

Neuro-oncology

2024/3/19

Patrick Roth
Patrick Roth

H-Index: 9

James Perry
James Perry

H-Index: 30

Matthias Preusser
Matthias Preusser

H-Index: 55

Warren Mason
Warren Mason

H-Index: 46

Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma

Molecular cancer therapeutics

2024/3/1

Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults

2024

Christopher Hahn
Christopher Hahn

H-Index: 32

Grayson Beecher
Grayson Beecher

H-Index: 7

Warren Mason
Warren Mason

H-Index: 46

Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma

Neuro-Oncology Advances

2024/1/1

Vikas Patil
Vikas Patil

H-Index: 15

Phedias Diamandis
Phedias Diamandis

H-Index: 17

Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma

Neuro-Oncology Practice

2023/2/1

QOL-26. A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2DIFFUSE GLIOMA (INDIGO …

Neuro-Oncology

2023/11/1

Mehdi Touat
Mehdi Touat

H-Index: 19

Warren Mason
Warren Mason

H-Index: 46

Matthias Holdhoff
Matthias Holdhoff

H-Index: 24

Yoshiki Arakawa
Yoshiki Arakawa

H-Index: 23

Wolfgang Wick
Wolfgang Wick

H-Index: 92

James Perry
James Perry

H-Index: 30

Dan Zhao
Dan Zhao

H-Index: 14

Islam Hassan
Islam Hassan

H-Index: 11

Timothy Cloughesy
Timothy Cloughesy

H-Index: 78

Focal Adhesion Kinase as a Therapeutic Target for Meningiomas With Somatic Neurofibromatosis Type 2 Mutations

Journal of Clinical Oncology

2023/1/20

CTNI-51. A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2 DIFFUSE GLIOMA (INDIGO …

Neuro-Oncology

2023/11/1

Timothy Cloughesy
Timothy Cloughesy

H-Index: 78

Mehdi Touat
Mehdi Touat

H-Index: 19

Warren Mason
Warren Mason

H-Index: 46

Matthias Holdhoff
Matthias Holdhoff

H-Index: 24

Yoshiki Arakawa
Yoshiki Arakawa

H-Index: 23

Wolfgang Wick
Wolfgang Wick

H-Index: 92

James Perry
James Perry

H-Index: 30

Dan Zhao
Dan Zhao

H-Index: 14

Islam Hassan
Islam Hassan

H-Index: 11

JOURNAL MEDICINE

2023

CTIM-19. ONCOLYTIC DNX-2401 VIROTHERAPY PLUS PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA: A PHASE 1/2 TRIAL

Neuro-Oncology

2023/11/1

Vikas Patil
Vikas Patil

H-Index: 15

Jeff Liu
Jeff Liu

H-Index: 19

Timothy Cloughesy
Timothy Cloughesy

H-Index: 78

Robert Aiken
Robert Aiken

H-Index: 11

Rohan Ramakrishna
Rohan Ramakrishna

H-Index: 18

Maxim Yankelevich
Maxim Yankelevich

H-Index: 6

Suresh Nair
Suresh Nair

H-Index: 14

Warren Mason
Warren Mason

H-Index: 46

498O INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma

Annals of Oncology

2023/10/1

INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION

2023/10/1

Mehdi Touat
Mehdi Touat

H-Index: 19

Wolfgang Wick
Wolfgang Wick

H-Index: 92

Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies in glioblastoma: an update

2023/9/15

Vorasidenib in IDH1-or IDH2-mutant low-grade glioma

New England Journal of Medicine

2023/8/17

Mehdi Touat
Mehdi Touat

H-Index: 19

Matthias Holdhoff
Matthias Holdhoff

H-Index: 24

Yoshiki Arakawa
Yoshiki Arakawa

H-Index: 23

Wolfgang Wick
Wolfgang Wick

H-Index: 92

Dan Zhao
Dan Zhao

H-Index: 14

Islam Hassan
Islam Hassan

H-Index: 11

ACQUIRED PTEN LOSS MAY MEDIATE DABRAFENIB AND TRAMETINIB RESISTANCE IN BRAF V600E–MUTATED EPITHELIOID GLIOBLASTOMA: A CASE REPORT

Neuro-Oncology Advances

2023/7

Abrar Ahmed
Abrar Ahmed

H-Index: 1

Warren Mason
Warren Mason

H-Index: 46

THE CLINICAL AND MOLECULAR LANDSCAPE OF GLIOMAS IN ADOLESCENTS AND YOUNG ADULTS

Neuro-Oncology Advances

2023/7

S Das
S Das

H-Index: 9

BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets

2023/7

Bevacizumab for cerebral radionecrosis: a single-center experience

Canadian Journal of Neurological Sciences

2023/7

LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE …

Neuro-Oncology

2023/11/1

Mehdi Touat
Mehdi Touat

H-Index: 19

Warren Mason
Warren Mason

H-Index: 46

Matthias Holdhoff
Matthias Holdhoff

H-Index: 24

Yoshiki Arakawa
Yoshiki Arakawa

H-Index: 23

Wolfgang Wick
Wolfgang Wick

H-Index: 92

James Perry
James Perry

H-Index: 30

Dan Zhao
Dan Zhao

H-Index: 14

Islam Hassan
Islam Hassan

H-Index: 11

Timothy Cloughesy
Timothy Cloughesy

H-Index: 78

See List of Professors in Warren Mason University(University of Toronto)

Co-Authors

academic-engine

Useful Links

List of top 50 universities
List of top 100 universities
List of top 500 universities
Find Professors Email
Find Universities Email
CUFinder Academic Engine